Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
Ontology highlight
ABSTRACT: There is an unmet medical need for anabolic treatments to restore lost bone. Human genetic bone disorders provide insight into bone regulatory processes. Sclerosteosis is a disease typified by high bone mass due to the loss of SOST expression. Sclerostin, the SOST gene protein product, competed with the type I and type II bone morphogenetic protein (BMP) receptors for binding to BMPs, decreased BMP signaling and suppressed mineralization of osteoblastic cells. SOST expression was detected in cultured osteoblasts and in mineralizing areas of the skeleton, but not in osteoclasts. Strong expression in osteocytes suggested that sclerostin expressed by these central regulatory cells mediates bone homeostasis. Transgenic mice overexpressing SOST exhibited low bone mass and decreased bone strengt
SUBMITTER: Winkler DG
PROVIDER: S-EPMC291840 | biostudies-literature | 2003 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA